Pfizer Inc. $PFE Shares Sold by Croban

Croban trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 9.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,685 shares of the biopharmaceutical company’s stock after selling 2,528 shares during the quarter. Croban’s holdings in Pfizer were worth $622,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. First Fiduciary Investment Counsel Inc. lifted its stake in Pfizer by 2.1% in the second quarter. First Fiduciary Investment Counsel Inc. now owns 237,043 shares of the biopharmaceutical company’s stock valued at $5,746,000 after buying an additional 4,928 shares during the last quarter. Strengthening Families & Communities LLC lifted its stake in Pfizer by 871.3% in the second quarter. Strengthening Families & Communities LLC now owns 2,370 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 2,126 shares during the last quarter. Blue Trust Inc. lifted its stake in Pfizer by 3.1% in the second quarter. Blue Trust Inc. now owns 118,351 shares of the biopharmaceutical company’s stock valued at $2,869,000 after buying an additional 3,548 shares during the last quarter. Fourpath Capital Management LLC lifted its stake in Pfizer by 19.8% in the second quarter. Fourpath Capital Management LLC now owns 36,855 shares of the biopharmaceutical company’s stock valued at $893,000 after buying an additional 6,095 shares during the last quarter. Finally, Thompson Investment Management Inc. lifted its stake in Pfizer by 1.3% in the second quarter. Thompson Investment Management Inc. now owns 415,996 shares of the biopharmaceutical company’s stock valued at $10,084,000 after buying an additional 5,151 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Bank of America upped their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, UBS Group restated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.35.

Pfizer Trading Down 1.7%

NYSE:PFE opened at $24.81 on Friday. The stock has a fifty day moving average price of $24.86 and a two-hundred day moving average price of $24.14. The stock has a market capitalization of $141.03 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 0.83 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.82.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.